YMAB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
YMAB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-12-15), Y-mAbs Therapeutics's share price is $9.43. Y-mAbs Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.
The historical rank and industry rank for Y-mAbs Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:
As of today (2024-12-15), Y-mAbs Therapeutics's share price is $9.43. Y-mAbs Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.54. Therefore, Y-mAbs Therapeutics's PE Ratio (TTM) for today is At Loss.
As of today (2024-12-15), Y-mAbs Therapeutics's share price is $9.43. Y-mAbs Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.54. Therefore, Y-mAbs Therapeutics's PE Ratio without NRI for today is At Loss.
The historical data trend for Y-mAbs Therapeutics's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y-mAbs Therapeutics Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | - | - | - | - |
Y-mAbs Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Y-mAbs Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Y-mAbs Therapeutics's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Y-mAbs Therapeutics's Price-to-Owner-Earnings for today is calculated as
Price-to-Owner-Earnings | = | Share Price | / | Owner Earnings per Share (TTM) |
= | 9.43 | / | -0.81 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y-mAbs Therapeutics (NAS:YMAB) Price-to-Owner-Earnings Explanation
For how to get Owner Earnings per Share (TTM), please click.
Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas Gad | director, officer: President and Chairman | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Torben Lund-hansen | officer: Sr. VP and Head of Tech Op | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Joris Wilms | officer: Sr. VP and COO | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Gerard Ber | director | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Bo Kruse | director, officer: EVP, CFO, Secy & Treas. | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Susan Laura Smith | officer: Senior Vice President, CCO | 5 OVERLOOK CT, LAMBERTVILLE NJ 08530 |
Vignesh Rajah | officer: SVP and CMO | HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950 |
Johan Wedell-wedellsborg | director, 10 percent owner | RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960 |
Biotech Aps Wg | 10 percent owner | RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960 |
Michael J Rossi | director, officer: President & CEO | 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
David N Gill | director | C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843 |
Juan Moller San Pedro Claus | director, officer: Chief Executive Officer | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169 |
Laura Hamill | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Mahiuddin Ahmed | officer: Sr. VP and CSO | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
Philip Karl Herman | officer: Sr. VP and CCO | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
From GuruFocus
By Marketwired • 07-01-2024
By GuruFocus News • 11-09-2024
By Marketwired • 09-03-2024
By Marketwired • 06-05-2024
By GuruFocus News • 11-15-2024
By Marketwired • 06-01-2024
By Marketwired • 08-05-2024
By GlobeNewswire • 06-01-2024
By Marketwired • 06-01-2024
By GuruFocus News • 11-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.